U.S. Pharmacist eNewsletter
April 2023

FDA Revises Guidance on Ibuprofen Oral Suspension
The ongoing ibuprofen oral suspensions shortage has impacted hospitals and healthcare facilities, which frequently use the medication to treat pain and fever in pediatric patients. To address this issue, the FDA issued guidance encouraging drug manufacturers to increase production and prioritize distribution to healthcare facilities. By customizing medications, compounding pharmacists can help meet demand. Read more.


Azurity Pharmaceuticals’ Konvomep Now FDA Approved
Azurity Pharmaceuticals recently announced that the FDA approved Konvomep (omeprazole and sodium bicarbonate for oral suspension). Konvomep is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients. It is expected that Konvomep will become commercially available in pharmacies nationwide in the first quarter of 2023. Read more.

New Pharmacist Recommendation Series Video
In the latest Pharmacist Recommendation Series video, U.S. Pharmacist Editor-in-Chief Robert Davidson discusses KONVOMEP with Clinical Pharmacist Tammie Lee Demler. In this installment, Dr. Demler explains how Konvomep may give patients, particularly people with difficulty swallowing pills or capsules, an option for treatment tailored to their needs. Click here to view video.

Connect With U.S. Pharmacist